Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma.
Corren J, Wechsler ME, Chupp G, Roseti SL, Hellqvist Å, Martin N, Llanos JP, Ambrose CS, Colice G. Corren J, et al. Among authors: wechsler me. J Allergy Clin Immunol Pract. 2023 Mar;11(3):943-945.e2. doi: 10.1016/j.jaip.2022.10.042. Epub 2022 Nov 11. J Allergy Clin Immunol Pract. 2023. PMID: 36375743 No abstract available.
Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
Corren J, Brightling CE, Boulet LP, Porsbjerg C, Wechsler ME, Menzies-Gow A, Ambrose CS, Cook B, Martin N, Spahn J, Llanos JP. Corren J, et al. Among authors: wechsler me. Eur Respir J. 2023 Mar 30;61(3):2202202. doi: 10.1183/13993003.02202-2022. Print 2023 Mar. Eur Respir J. 2023. PMID: 36997233 Free article. No abstract available.
Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry.
Chen W, Tran TN, Sadatsafavi M, Murray R, Wong NCB, Ali N, Ariti C, Bulathsinhala L, Gil EG, FitzGerald JM, Alacqua M, Al-Ahmad M, Altraja A, Al-Lehebi R, Bhutani M, Bjermer L, Bjerrum AS, Bourdin A, von Bülow A, Busby J, Canonica GW, Carter V, Christoff GC, Cosio BG, Costello RW, Fonseca JA, Gibson PG, Yoo KH, Heaney LG, Heffler E, Hew M, Hilberg O, Hoyte F, Iwanaga T, Jackson DJ, Jones RC, Koh MS, Kuna P, Larenas-Linnemann D, Lehmann S, Lehtimäki L, Lyu J, Mahboub B, Maspero J, Menzies-Gow AN, Newell A, Sirena C, Papadopoulos NG, Papaioannou AI, Perez-de-Llano L, Perng Steve DW, Peters M, Pfeffer PE, Porsbjerg CM, Popov TA, Rhee CK, Salvi S, Taillé C, Taube C, Torres-Duque CA, Ulrik C, Ra SW, Wang E, Wechsler ME, Price DB. Chen W, et al. Among authors: wechsler me. J Allergy Clin Immunol Pract. 2023 Sep;11(9):2732-2747. doi: 10.1016/j.jaip.2023.05.044. Epub 2023 Jun 8. J Allergy Clin Immunol Pract. 2023. PMID: 37301430 Free article.
Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies.
Corren J, Menzies-Gow A, Bimmel J, McGuinness A, Almqvist G, Bowen K, Griffiths JM, Ponnarambil S, Bourdin A, Israel E, Colice G, Brightling CE, Wechsler ME; PATHWAY and NAVIGATOR study investigators. Corren J, et al. Among authors: wechsler me. Immunotherapy. 2023 Nov;15(16):1327-1340. doi: 10.2217/imt-2023-0109. Epub 2023 Sep 29. Immunotherapy. 2023. PMID: 37772607 Review.
Are We Ready for Asthma Remission as a Clinical Outcome?
Lugogo NL, Mohan A, Akuthota P, Couillard S, Rhoads S, Wechsler ME. Lugogo NL, et al. Among authors: wechsler me. Chest. 2023 Oct;164(4):831-834. doi: 10.1016/j.chest.2023.04.028. Chest. 2023. PMID: 37805244 Free PMC article. No abstract available.
Exploring Definitions and Predictors of Response to Biologics for Severe Asthma.
Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, Al-Ahmad M, Al-Lehebi R, Altraja A, Beastall A, Bergeron C, Bjermer L, Bjerrum AS, Cano-Rosales DJ, Canonica GW, Carter V, Charriot J, Christoff GC, Cosio BG, Denton E, Fernandez-Sanchez MJ, Fonseca JA, Gibson PG, Goh C, Heaney LG, Heffler E, Hew M, Iwanaga T, Katial R, Koh MS, Kuna P, Larenas-Linnemann D, Lehtimäki L, Mahboub B, Martin N, Matsumoto H, Menzies-Gow AN, Papadopoulos NG, Patel P, Perez-De-Llano L, Peters M, Pfeffer PE, Popov TA, Porsbjerg CM, Rhee CK, Sadatsafavi M, Taillé C, Torres-Duque CA, Tsai MJ, Ulrik CS, Upham JW, von Bülow A, Wang E, Wechsler ME, Price DB. Scelo G, et al. Among authors: wechsler me. J Allergy Clin Immunol Pract. 2024 Sep;12(9):2347-2361. doi: 10.1016/j.jaip.2024.05.016. Epub 2024 May 19. J Allergy Clin Immunol Pract. 2024. PMID: 38768896 Free article.
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
Carr TF, Moore WC, Kraft M, Brusselle G, Castro M, Chupp GL, Wechsler ME, Hunter G, Lindsley AW, Llanos JP, Burke LK, Chandarana S, Ambrose CS. Carr TF, et al. Among authors: wechsler me. Adv Ther. 2024 Jul;41(7):2978-2990. doi: 10.1007/s12325-024-02889-8. Epub 2024 May 27. Adv Ther. 2024. PMID: 38802635 Free PMC article. Clinical Trial.
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE. Wechsler ME, et al. Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024. Online ahead of print. Eur Respir J. 2024. PMID: 39326921 Free article.
295 results